human allogeneic bone marrow derived osteoblastic cells | |
---|---|
Trade Name | |
Orphan Indication | Osteogenesis imperfecta |
USA Market Approval | USA |
USA Designation Date | 2015-11-09 00:00:00 |
Sponsor | Bone Therapeutics SA;37, Rue Auguste Piccard, Gosselies;Gosselies |
Related Access Program
Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia
Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia
AbbVie – Acute Myeloid Leukemia (AML)
University of California, San Francisco – Acute Myeloid Leukemia
Emory University – Acute Myeloid Leukemia
British Columbia Cancer Agency – Thyroid Cancer, Medullary
Novartis Pharmaceuticals – Acute Myeloid Leukemia (AML) With
Beijing Cancer Hospital – Thyroid Nodules
Alnylam Pharmaceuticals – Amyloidosis, Hereditary
Alnylam Pharmaceuticals – TTR-mediated Amyloidosis
Astellas Pharma Global Development, Inc. – Acute Myeloid Leukemia (AML)